Entellus Medical plans to conduct initial public offering of stock

Offering finances medical technology product development and research

By Devika Patel

Knoxville, Tenn., Dec. 23 – Entellus Medical, Inc. will price an initial public sale of its common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

BofA Merrill Lynch and Piper Jaffray are the bookrunners, and William Blair and Canaccord Genuity are the co-managers.

Proceeds will be used for product development and clinical research, sales, marketing, working capital, and general corporate purposes.

Based in Plymouth, Minn., the medical technology company is focused on sinusitis. It expects its shares will trade on the Nasdaq under the symbol “ENTL.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.